Population pharmacokinetics of ampicillin and sulbactam in patients with community-acquired pneumonia: Evaluation of the impact of renal impairment

British Journal of Clinical Pharmacology

Volumn 77, Issue 3, 2014, Pages 509-521

  Soto, Elena ^a   Shoji, Satoshi ^b   Muto, Chieko ^b   Tomono, Yoshiro ^b   Marshall, Scott ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

ampicillin; pneumonia; population pharmacokinetics; sulbactam; Unasyn

Indexed keywords

AMPICILLIN; PNEUMONIA; POPULATION PHARMACOKINETICS; SULBACTAM; UNASYN;

ADULT; AGED; AGED, 80 AND OVER; AMPICILLIN; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; COMPUTER SIMULATION; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG DOSAGE CALCULATIONS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; JAPAN; KIDNEY; KIDNEY DISEASES; MALE; METABOLIC CLEARANCE RATE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MODELS, BIOLOGICAL; PNEUMONIA, BACTERIAL; SULBACTAM;

EID: 84894471385     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12232     Document Type: Article

References (27)

1. USP, UNASYN® (ampicillin sodium/sulbactam sodium), Jan 2012.
2. Levin AS,. Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem. Clin Microbiol Infect 2002; 8: 144-153.
3. Ripa S, Ferrante L, Prenna M,. Pharmacokinetics of sulbactam/ampicillin in humans after intravenous and intramuscular injection. Chemotherapy 1990; 36: 185-192.
4. Foulds G,. Pharmacokinetics of sulbactam/ampicillin in humans: a review. Rev Infect Dis 1986; 8: S503-511.
5. Noguchi JK, Gill MA,. Sulbactam: a β-lactamase inhibitor. Clin Pharm 1988; 7: 37-51.
6. Benson JM, Nahata MC,. Sulbactam/ampicillin, a new beta-lactam inhibitor /beta-lactam antibiotic combination. Drug Intell Clin Pharm 1988; 22: 534-541.
7. Blum RA, Kohli RK, Harrison NJ, Schentag JJ,. Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis. Antimicrob Agents Chemother 1989; 33: 1470-1476.
8. Jacobs MR,. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect 2001; 7: 589-596.
9. Drusano GL,. Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia. Eur Respir Rev. 2007; 16: 45-49.
10. Drusano GL,. Prevention of resistance: a goal for dose selection for antimicrobial agents. clinical. infectious diseases 2003; 36: S42-50.
11. Pfizer Inc. A multicenter, unblinded, non-comparative study of Unasyn-S 12 g/day evaluating the safety and efficacy in Japanese adult subjects with community acquired pneumonia. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US), 2000. Available at http://clinicaltrials.gov/ ct2/show/results/NCT01189487 (last accessed 4 February 2013). NLM Identifier:NCT01189487.
12. Shiba K, Saito A, Shimada J, Omori M, Yamaji T, Houjou T, Kaji M, Okuda S, Hori S, Miyahara T, Ueda Y,. Clinical studies on sulbactam-ampicillin. Chemotherapy 1988; 36: 149-159.
13. Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Landry ML,. Manual of Clinical Microbiology, ninth edn. Washington, DC: ASM Press, 2007.
14. Clinical and Laboratory Standards Institute. 2012: Available at http://www.clsi.org/ (accessed 25 July 2012).
15. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
16. Beal SL, Sheiner LB, Boeckmann AJ, eds. NONMEM Users Guides. Ellicott City, MD: ICON Development Solutions, 1989-2006.
17. Lindbom L, Ribbing J, Jonsson EN,. Perl-speaks-NONMEM (PsN)-a perl module for NONMEM related programming. Comput Methods Programs Biomed 2004; 75: 85-94.
18. Hooker AC, Staatz CE, Karlsson MO,. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res 2007; 24: 2187-2197.
19. Karlsson MO, Savic RM,. Diagnosing model diagnostics. Clin Pharmacol Ther 2007; 82: 17-20.
20. Savic RM, Karlsson MO,. Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J 2009; 11: 558-569.
21. Anderson BJ, Holford NHG,. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48: 303-332.
22. Lalonde RL, Wagner JA,. Drug development perspective on pharmacokinetic studies of new drugs in patients with renal impairment. Clin Pharmacol Ther 2009; 86: 557-561.
23. Levey AS, Bosch JP, Lewis JB, Greence T, Rogers N, Roth D,. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
24. Winter ME,. Basic Clinical Pharmacokinetics, 3rd edn. Washington, DC: Applied therapeutics Inc. Sixth Printing, 1999; 93-103.
25. Michels WM, Grootendorst DC, Verduijn M, Elliott EG, Dekker FW, Krediet RT,. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol 2010; 5: 1003-1009.
26. Stevens LA, Coresh J, Greene T, Levey AS,. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473-2483.
27. The European Committee on Antimicrobial Susceptibility Testing-EUCAST. Available at http://www.eucast.org/ (accessed 19 November 2012)